Oral Antifungal Therapy for Refractory Diaper Candidiasis in Pediatrics

Primary Recommendation

The American Academy of Pediatrics recommends a loading dose of 6 mg/kg on day 1 for pediatric patients with diaper area Candida infection, as per the FDA-approved pediatric dosing 1

Severe infection requiring systemic therapy may be present when topical antifungals fail in diaper dermatitis with Candida, as suggested by Clinical Infectious Diseases 2
Possible deep tissue involvement may also be a factor when topical antifungals fail, as noted by MMWR Recommendations and Reports 3
Inadequate topical penetration due to moisture/occlusion in the diaper area can limit topical efficacy, making systemic therapy more appropriate for refractory cases, according to Clinical Infectious Diseases 2

For children ≥15 years, the recommended dosing is 100-200 mg daily rather than weight-based dosing, as per Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1

Oral itraconazole solution can be used as an alternative, with a dose of 2.5 mg/kg twice daily (maximum 200 mg/day) for 14 days, as recommended by MMWR Recommendations and Reports 3
For severe or invasive disease, caspofungin can be used with a loading dose of 70 mg/m², then 50 mg/m²/day IV, as suggested by Clinical Microbiology and Infection 4 and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5
Micafungin can also be used for severe or invasive disease, with a dose of 2-4 mg/kg/day IV, according to Clinical Microbiology and Infection 4 and Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5
Liposomal amphotericin B can be used for severe or invasive disease, with a dose of 3 mg/kg/day IV, as recommended by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5

The Centers for Disease Control and Prevention suggests that clinical response should be evident within 7 days of starting oral fluconazole, and if no improvement is seen, fungal culture and consideration of resistant species should be undertaken, as noted by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1

Fluconazole has >93% oral bioavailability, making oral and IV formulations bioequivalent, as stated by Praxis Medical Insights: Practical Summaries of Clinical Guidelines 1

Adequate topical therapy should be ensured before escalating to oral therapy, including proper diaper hygiene measures and adequate duration of topical therapy, as suggested by Clinical Infectious Diseases 2